Once-daily atazanavir/ritonavir versus twice-daily lopi with tenofovir and emtricitabine, for management of ar patients: 48 week efficacy and safety results of the CAST

Lancet, The

372, 646-655

DOI: 10.1016/s0140-6736(08)61081-8

Citation Report

#	Article	IF	Citations
1	Antiretroviral therapy: When to start and which drugs to use. Current Infectious Disease Reports, 2008, 10, 332-339.	1.3	4
2	British HIV Association guidelines for the treatment of HIVâ€1â€infected adults with antiretroviral therapy 2008. HIV Medicine, 2008, 9, 563-608.	1.0	530
6	A king in the CASTLE? Optimum initial HIV protease inhibitor. Lancet, The, 2008, 372, 604-606.	6.3	2
7	Atazanavir: its role in HIV treatment. Expert Review of Anti-Infective Therapy, 2008, 6, 785-796.	2.0	37
8	Antiretroviral Treatment of Adult HIV Infection. JAMA - Journal of the American Medical Association, 2008, 300, 555.	3.8	846
9	Kidney Disease in Patients with HIV Infection and AIDS. Clinical Infectious Diseases, 2008, 47, 1449-1457.	2.9	95
10	Role of atazanavir in the treatment of HIV infection. Therapeutics and Clinical Risk Management, 0, , 99.	0.9	2
11	Pharmacotherapy of HIV: A Focus on Atazanavir/Ritonavir a Potent and Convenient Once Daily Ritonavir Boosted Protease-Inhibitor for HIV-1 Infected Adults. Clinical Medicine Therapeutics, 2009, 1, CMT.S1088.	0.1	0
13	The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients. Expert Review of Anti-Infective Therapy, 2009, 7, 801-805.	2.0	3
14	Significant publications on infectious diseases pharmacotherapy in 2008. American Journal of Health-System Pharmacy, 2009, 66, 1726-1734.	0.5	11
15	High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatmentâ€Experienced Patients Infected with Multidrugâ€Resistant HIV: Results of the ANRS 139 TRIO Trial. Clinical Infectious Diseases, 2009, 49, 1441-1449.	2.9	213
16	Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review. Journal of Antimicrobial Chemotherapy, 2009, 64, 239-250.	1.3	50
17	Monotherapy with Lopinavir/Ritonavir as Maintenance After HIV-1 Viral Suppression: Results of a 96-Week Randomized, Controlled, Open-Label, Pilot Trial (KalMo Study). HIV Clinical Trials, 2009, 10, 368-374.	2.0	50
18	Baseline Lipid Levels Rather Than the Presence of Reported Body Shape Changes Determine the Degree of Improvement in Lipid Levels After Switching to Atazanavir. HIV Clinical Trials, 2009, 10, 168-180.	2.0	4
19	Mechanisms of HIV-related dyslipidemia. HIV Therapy, 2009, 3, 283-292.	0.6	0
20	HIV protease inhibitors: recent clinical trials and recommendations on use. Expert Opinion on Pharmacotherapy, 2009, 10, 1615-1629.	0.9	38
21	The ARTEMIS trial: once-daily darunavir/ritonavir in the management of treatment-naive, HIV-infected patients. HIV Therapy, 2009, 3, 121-133.	0.6	1
22	Maintaining Reduced Viral Fitness and CD4 Response in HIVâ€Infected Patients with Viremia Receiving a Boosted Protease Inhibitor. Clinical Infectious Diseases, 2009, 48, 680-682.	2.9	5

#	Article	IF	Citations
23	Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study. Journal of Antimicrobial Chemotherapy, 2009, 64, 118-125.	1.3	35
25	Antiretroviral therapy for treatment-naÃ¯ve patients: A review of recent literature and the updated guidelines. Current Infectious Disease Reports, 2009, 11, 311-318.	1.3	1
26	Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study. Advances in Therapy, 2009, 26, 185-193.	1.3	15
28	Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial. HIV Medicine, 2009, 10, 620-626.	1.0	4
29	The nephrotoxic effects of HAART. Nature Reviews Nephrology, 2009, 5, 563-573.	4.1	121
31	Emtricitabine/Tenofovir Disoproxil Fumarate. Drugs, 2009, 69, 843-857.	4.9	9
32	Atazanavir. Drugs, 2009, 69, 1107-1140.	4.9	89
33	New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Expert Opinion on Pharmacotherapy, 2009, 10, 2445-2466.	0.9	68
34	Clinical pharmacology, efficacy and safety of atazanavir: a review. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 1455-1468.	1.5	30
35	Efficacy and safety of boosted atazanavir in HIV-infected, ARV-naive patients â€" results from 48/96 weeks Castle study. HIV and AIDS Review, 2009, 8, 5-8.	0.1	0
36	Efficacy and safety of atazanavir-based regimens in routine management of HIV-infected adults. HIV and AIDS Review, 2009, 8, 9-11.	0.1	0
37	Atazanavir, a promising option in therapy in HIV infected patients with liver injury and hyperbilirubinemia â€" a case report. HIV and AIDS Review, 2009, 8, 23-25.	0.1	0
39	Improvements in antiretroviral therapy outcomes over calendar time. Current Opinion in HIV and AIDS, 2009, 4, 194-199.	1.5	50
40	Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. Aids, 2009, 23, 817-824.	1.0	212
41	Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. Aids, 2009, 23, 1349-1357.	1.0	47
42	Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. Aids, 2009, 23, 1829-1840.	1.0	53
43	Gemini: A Noninferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV-1 Therapy in Adults. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 50, 367-374.	0.9	108
44	Effect of Baseline CD4 Cell Counts on the Clinical Significance of Short-Term Immunologic Response to Antiretroviral Therapy in Individuals With Virologic Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 357-363.	0.9	26

#	Article	IF	Citations
45	Multidrug resistance: a clinical approach. Current Opinion in HIV and AIDS, 2009, 4, 499-506.	1.5	3
46	Efficacy and Safety of Switching From Boosted Lopinavir to Boosted Atazanavir in Patients With Virological Suppression Receiving a LPV/r-Containing HAART: The ATAZIP Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 29-36.	0.9	81
47	Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir Administered with Abacavir/Lamivudine Once Daily in Antiretroviral-NaÃ¯ve HIV-1â€“Infected Adult Subjects. HIV Clinical Trials, 2009, 10, 356-367.	2.0	15
48	Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. Aids, 2009, 23, 1547-1556.	1.0	195
49	Raltegravir in treatment naÃ¯ve patients. European Journal of Medical Research, 2009, 14, 22.	0.9	5
50	First-line regimen failure of antiretroviral therapy: a clinical and evidence-based approach. Current Opinion in HIV and AIDS, 2009, 4, 493-498.	1.5	2
51	Factors predictive of virological failure on atazanavir in 310 HIV-infected patients. Aids, 2010, 24, 1593-1595.	1.0	6
52	Potential Confounding of the Association Between Exposure to Nucleoside Analogues and Mitochondrial Dysfunction in HIV-Uninfected and Indeterminate Infants. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 154-157.	0.9	9
53	Does earlier HIV RNA suppression provide long-term benefits?. Aids, 2010, 24, 1591-1593.	1.0	3
54	Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. Aids, 2010, 24, 1598-1601.	1.0	179
55	Long-Term Outcomes of a National Expanded Access Program to Antiretroviral Therapy: The Chilean AIDS Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 368-374.	0.9	26
56	From lipodystrophy to cardiovascular disease: new insight into the management of HIV infection. Clinical Lipidology, 2010, 5, 583-593.	0.4	0
57	Effect of Nevirapine on the Steady-State Trough Concentrations of Atazanavir in HIV-Infected Patients Receiving Atazanavir/Ritonavir. Therapeutic Drug Monitoring, 2010, 32, 93-96.	1.0	6
58	HIV protease inhibitors and obesity. Current Opinion in Endocrinology, Diabetes and Obesity, 2010, 17, 478-485.	1.2	43
59	The impact of CCL3L1 copy number in an HIV-1-infected white population. Aids, 2010, 24, 1589-1591.	1.0	6
60	Is There Any Potential for First-Line Etravirine Use? Analysis From a Large Data Set of Antiretroviral Therapy-Naive HIV-Infected Patients Undergoing Resistance Test. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 150-151.	0.9	0
63	Sequencing of antiretroviral therapy in children in low- and middle-income countries. Current Opinion in HIV and AIDS, 2010, 5, 54-60.	1.5	15
64	No detection of HIV 1-RNA in semen of men on efficient HAART in the past 4 years of a 2002â€“2009 survey. Aids, 2010, 24, 1595-1598.	1.0	18

#	Article	IF	Citations
66	Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1â€“Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 323-332.	0.9	237
67	1. Antiviral Agents for HIV Infected Patients.. The Journal of the Japanese Society of Internal Medicine, 2010, 99, 1574-1582.	0.0	0
68	Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. Antiviral Therapy, 2010, 15, 993-1002.	0.6	35
69	Management of Late-presenting Patients with HIV Infection. Antiviral Therapy, 2010, 15, 25-30.	0.6	22
70	Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals. Antiviral Therapy, 2010, 15, 1107-1114.	0.6	28
71	Treatment Modification in Human Immunodeficiency Virusâ€“Infected Individuals Starting Combination Antiretroviral Therapy Between 2005 and 2008. Archives of Internal Medicine, 2010, 170, 57.	4.3	127
72	Broadening the perspective when assessing evidence on boosted protease inhibitor-based regimens for initial antiretroviral therapy. Advances in Therapy, 2010, 27, 763-773.	1.3	1
73	Deconstructing Most Recent Antiretroviral Recommendations. Current HIV/AIDS Reports, 2010, 7, 77-84.	1.1	3
74	The HIV-Infected Adolescent. Current Infectious Disease Reports, 2010, 12, 63-70.	1.3	9
75	Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. Antiviral Research, 2010, 85, 59-74.	1.9	286
76	Understanding and managing the adverse effects of antiretroviral therapy. Antiviral Research, 2010, 85, 201-209.	1.9	155
77	Low rate of virological failure and maintenance of susceptibility to HIVâ€1 protease inhibitors with firstâ€line lopinavir/ritonavirâ€based antiretroviral treatment in clinical practice. Journal of Medical Virology, 2010, 82, 1996-2003.	2.5	6
78	Efficacy and safety of boosted and unboosted atazanavirâ€containing antiretroviral regimens in real life: results from a multicentre cohort study. HIV Medicine, 2010, 11, 40-45.	1.0	29
79	Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100â€ƒmg in treatment-naÃ¯ve HIV-infected patients*. HIV Medicine, 2010, 11, 666-669.	1.0	6
81	Challenges in Initiating Antiretroviral Therapy in 2010. Canadian Journal of Infectious Diseases and Medical Microbiology, 2010, 21, 1C-15C.	0.7	1
82	Long-term treatment of patients with HIV-1: the role of atazanavir. HIV/AIDS - Research and Palliative Care, 2010, 2, 157.	0.4	1
83	Prospective, Randomized, Open Label Trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ Treatment-Naive Subjects With CD4+<200 cell/mm3 in Mexico. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 582-588.	0.9	59
84	Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options. Journal of Antimicrobial Chemotherapy, 2010, 65, 1094-1099.	1.3	30

#	Article	IF	Citations
85	When and why to start antiretroviral therapy?. Journal of Antimicrobial Chemotherapy, 2010, 65, 383-385.	1.3	8
86	Efavirenz versus Boosted Atazanavir or Zidovudine and Abacavir in Antiretroviral Treatmentâ€“Naive, HIVâ€Infected Subjects: Week 48 Data from the Altair Study. Clinical Infectious Diseases, 2010, 51, 855-864.	2.9	57
87	Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trials. International Journal of Epidemiology, 2010, 39, 1567-1581.	0.9	25
88	Instantaneous Inhibitory Potential Is Similar to Inhibitory Quotient at Predicting HIVâ€1 Response to Antiretroviral Therapy. Clinical Infectious Diseases, 2010, 51, 93-98.	2.9	30
89	Factors influencing lopinavir and atazanavir plasma concentration. Journal of Antimicrobial Chemotherapy, 2010, 65, 129-137.	1.3	23
90	Efficacy and Safety of Unboosted Atazanavir in Combination with Lamivudine and Didanosine in Naive HIV Type 1 Patients in Senegal. AIDS Research and Human Retroviruses, 2010, 26, 519-525.	0.5	2
91	Impact of Low Abundance HIV Variants on Response to Ritonavir-Boosted Atazanavir or Fosamprenavir Given Once Daily with Tenofovir/Emtricitabine in Antiretroviral-Naive HIV-Infected Patients. AIDS Research and Human Retroviruses, 2010, 26, 407-417.	0.5	9
92	Maraviroc versus Efavirenz, Both in Combination with Zidovudineâ€Lamivudine, for the Treatment of Antiretroviralâ€Naive Subjects with CCR5â€Tropic HIVâ€1 Infection. Journal of Infectious Diseases, 2010, 201, 803-813.	1.9	241
93	Differential Effects of Efavirenz, Lopinavir/r, and Atazanavir/r on the Initial Viral Decay Rate in Treatment NaÃ¯ve HIV-1â€“Infected Patients. AIDS Research and Human Retroviruses, 2010, 26, 533-540.	0.5	14
94	Gastrointestinal tolerability and quality of life in antiretroviral-naÃ¯ve HIV-1-infected patients: data from the CASTLE study. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2010, 22, 677-686.	0.6	27
95	Friedewald Equation Underestimates Low-Denisty Lipoprotein Elevations for Patients With High Triglyceride Levels in the ARTEMIS and TITAN Trials. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 151-153.	0.9	0
96	Avoid a Different Standard of Care When Applying Results of Development of Antiretroviral Therapy in Africa (DART) Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 153-154.	0.9	0
97	Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. Aids, 2010, 24, 2019-2027.	1.0	60
98	Comparative Cost-Efficacy Analysis of Darunavir/ritonavir and Other Ritonavir-Boosted Protease Inhibitors for First-Line Treatment of HIV-1 Infection in the United States. HIV Clinical Trials, 2010, 11, 133-144.	2.0	20
99	Safety and Efficacy of a 36-Week Induction Regimen of Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir in HIV-Infected Patients. HIV Clinical Trials, 2010, 11, 69-79.	2.0	25
100	Antiretroviral Therapies in Women after Single-Dose Nevirapine Exposure. New England Journal of Medicine, 2010, 363, 1499-1509.	13.9	117
102	Does lopinavir/ritonavir alter the primary gingival epithelium?. Expert Review of Anti-Infective Therapy, 2010, 8, 1345-1349.	2.0	1
103	Antiretroviral Medications: Adverse Effects on the Kidney. Advances in Chronic Kidney Disease, 2010, 17, 72-82.	0.6	54

#	Article	IF	Citations
104	Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy. The Cochrane Library, 2010, , CD006517.	1.5	14
105	Lopinavir/Ritonavir. Drugs, 2010, 70, 1885-1915.	4.9	103
106	Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy, 2010, 65, 1878-1888.	1.3	37
107	Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. Journal of Hepatology, 2010, 53, 238-244.	1.8	38
109	Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet, The, 2010, 375, 396-407.	6.3	276
110	Effectiveness of Boosted Protease Inhibitor-Based Regimens in HIV Type 1-Infected Patients Who Experienced Virological Failure with NNRTI-Based Antiretroviral Therapy in a Resource-Limited Setting. AIDS Research and Human Retroviruses, 2010, 26, 139-148.	0.5	13
111	96-Week Efficacy and Safety of Atazanavir, With and Without Ritonavir, in a HAART Regimen in Treatment-Naive Patients. Journal of the International Association of Providers of AIDS Care, 2010, 9, 34-42.	1.2	18
112	Treatment of advanced HIV disease in antiretroviral-naÃ¯ve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2011, 23, 1500-1504.	0.6	3
113	Effects of the H2-Receptor Antagonist Famotidine on the Pharmacokinetics of Atazanavir-Ritonavir With or Without Tenofovir in HIV-Infected Patients. AIDS Patient Care and STDs, 2011, 25, 509-515.	1.1	15
117	Comparative Effectiveness of Efavirenz, Protease Inhibitors, and Raltegravir-Based Regimens as First-Line Treatment for HIV-Infected Adults: A Mixed Treatment Comparison. HIV Clinical Trials, 2011, 12, 175-189.	2.0	15
118	Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 609-622.	1.5	15
122	Management of HIV infection in treatment-naive patients: A review of the most current recommendations. American Journal of Health-System Pharmacy, 2011, 68, 991-1001.	0.5	17
123	Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. ClinicoEconomics and Outcomes Research, 2011, 3, 197.	0.7	24
124	HIV protease inhibitors: present and future. Future Virology, 2011, 6, 571-580.	0.9	0
125	Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infectious Diseases, The, 2011, 11, 907-915.	4.6	175
127	Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committee. Canadian Journal of Infectious Diseases and Medical Microbiology, 2011, 22, 52-60.	0.7	6
128	Critical appraisal and update on tenofovir in management of human immunodeficiency virus infection. Virus Adaptation and Treatment, 2011, , 55.	1.5	3
129	Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-infected Koreans. Infection and Chemotherapy, 2011, 43, 89.	1.0	13

#	Article	IF	Citations
130	HIV and HAART-Associated Dyslipidemia. Open Cardiovascular Medicine Journal, 2011, 5, 49-63.	0.6	125
131	Clinical utility and long-term use of atazanavir in the treatment of HIV-1 infection. Virus Adaptation and Treatment, 0, , 25.	1.5	0
132	Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection. Aids, 2011, 25, 1881-1886.	1.0	80
133	Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). Aids, 2011, 25, 2113-2122.	1.0	132
134	Lopinavir/Ritonavir-based Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-infected Naive Children. Pediatric Infectious Disease Journal, 2011, 30, 684-688.	1.1	18
135	The use of atazanavir in HIV-infected patients with liver cirrhosis: lack of hepatotoxicity and no significant changes in bilirubin values or model for end-stage liver disease score. Aids, 2011, 25, 1006-1009.	1.0	8
136	Reduced Emergence of the M184V/I Resistance Mutation When Antiretroviral-NaÃ¯ve Subjects Use Emtricitabine Versus Lamivudine in Regimens Composed of Two NRTIs Plus the NNRTI Efavirenz. HIV Clinical Trials, 2011, 12, 61-70.	2.0	21
137	Lopinavir: the old champion. Future Virology, 2011, 6, 561-570.	0.9	1
138	Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1. Annals of Internal Medicine, 2011, 154, 445.	2.0	287
139	Nevirapine versus Atazanavir/Ritonavir, Each Combined with Tenofovir Disoproxil Fumarate/Emtricitabine, in Antiretroviral-Naive HIV-1 Patients: The Arten Trial. Antiviral Therapy, 2011, 16, 339-348.	0.6	89
140	Post-Exposure Prophylaxis for HIV Infection: A Clinical Trial Comparing Lopinavir/Ritonavir versus Atazanavir Each with Zidovudine/Lamivudine. Antiviral Therapy, 2012, 17, 337-346.	0.6	24
141	Changes in lipid profiles after switching to a protease inhibitor-containing cART - unfavourable effect of fosamprenavir in obese patients. European Journal of Medical Research, 2011, 16, 85.	0.9	5
142	Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naÃ¯ve HIV-1-infected patients (the ARTEN study). HIV Medicine, 2011, 12, 374-382.	1.0	30
143	Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women. HIV Medicine, 2011, 12, 570-579.	1.0	57
144	Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naÃ¯ve HIV-1-infected patients. HIV Medicine, 2011, 12, 620-631.	1.0	36
145	A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naÃ¯ve patients. International Journal of Clinical Practice, 2011, 65, 1240-1249.	0.8	21
146	Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease. BMC Infectious Diseases, 2011, 11, 341.	1.3	7
147	Management of HIV-1 associated hepatitis in patients with acquired immunodeficiency syndrome: role of a successful control of viral replication. AIDS Research and Therapy, 2011, 8, 9.	0.7	3

#	Article	IF	Citations
148	Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naÃ¯ve HIV-1 infected patients. Journal of Pharmacokinetics and Pharmacodynamics, 2011, 38, 727-742.	0.8	3
149	The prevalence and clinical significance of intestinal parasites in HIV-infected patients in Denmark. Scandinavian Journal of Infectious Diseases, 2011, 43, 129-135.	1.5	31
150	Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults. Future Virology, 2011, 6, 157-177.	0.9	41
152	Health Needs of HIV-Infected Women in the United States: Insights from The Women Living Positive Survey. AIDS Patient Care and STDs, 2011, 25, 279-285.	1.1	65
153	Effect of Low-Dose Omeprazole (20 mg Daily) on the Pharmacokinetics of Multiple-Dose Atazanavir With Ritonavir in Healthy Subjects. Journal of Clinical Pharmacology, 2011, 51, 368-377.	1.0	38
154	Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naÃ¯ve human immunodeficiency virus-infected patients in the United States. Journal of Medical Economics, 2011, 14, 167-178.	1.0	11
155	Severe Acute Renal Failure in an HIV-Infected Patient After Only 2 Weeks of Tenofovir-Based Antiretroviral Therapy. AIDS Patient Care and STDs, 2011, 25, 457-460.	1.1	11
156	Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study. Journal of Antimicrobial Chemotherapy, 2011, 66, 363-370.	1.3	61
157	Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir. Journal of Antimicrobial Chemotherapy, 2011, 66, 2075-2082.	1.3	20
158	Optimizing Initial Therapy for HIV Infection. Journal of Infectious Diseases, 2011, 204, 1154-1156.	1.9	1
159	Treatment Durability, Effectiveness, and Safety with Atazanavir/Ritonavir-Based HAART Regimen in Treatment-NaÃ¯ve HIV-Infected Patients. HIV Clinical Trials, 2011, 12, 151-160.	2.0	3
160	Optimum time to start antiretroviral therapy in patients with HIV-associated tuberculosis: before or after tuberculosis diagnosis?. Aids, 2011, 25, 1003-1006.	1.0	5
161	The rise and fall of methicillin-resistant Staphylococcus aureus infections in HIV patients. Aids, 2011, 25, 1001-1003.	1.0	23
162	Late Initiation of HAART Among HIV-Infected Patients in Spain Is Frequent and Related to a Higher Rate of Virological Failure but not to Immigrant Status. HIV Clinical Trials, 2011, 12, 1-8.	2.0	12
163	Ritonavir-boosted protease inhibitors in HIV therapy. Annals of Medicine, 2011, 43, 375-388.	1.5	110
164	Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers. Journal of Antimicrobial Chemotherapy, 2012, 67, 2013-2019.	1.3	8
165	Response to Antiretroviral Treatment After Failure of NNRTI Plus NRTIs-Based Therapy. Data from the ARCA Collaborative Group. Current HIV Research, 2012, 10, 334-340.	0.2	1
166	HIV-1 Amino Acid Changes Among Participants With Virologic Failure: Associations With First-line Efavirenz or Atazanavir Plus Ritonavir and Disease Status. Journal of Infectious Diseases, 2012, 206, 1920-1930.	1.9	18

#	Article	IF	Citations
167	The glory of guidelines and the twilight of reality: controversies and challenges in the prevention and treatment of HIV in children. Expert Review of Anti-Infective Therapy, 2012, 10, 761-774.	2.0	1
168	Etiology and Pharmacologic Management of Noninfectious Diarrhea in HIV-Infected Individuals in the Highly Active Antiretroviral Therapy Era. Clinical Infectious Diseases, 2012, 55, 860-867.	2.9	64
169	Diarrhea Associated with Lopinavir/Ritonavir-Based Therapy. Journal of the International Association of Providers of AIDS Care, 2012, 11, 252-259.	1.2	6
170	Very late initiation of HAART impairs treatment response at 48 and 96 weeks: results from a meta-analysis of randomized clinical trials. Journal of Antimicrobial Chemotherapy, 2012, 67, 312-321.	1.3	22
171	The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. Aids, 2012, 26, 1231-1241.	1.0	132
172	Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection. Archives of Internal Medicine, 2012, 172, 1313.	4.3	31
173	Type I aortic dissection in a patient with human immunodeficiency virus infection. BioScience Trends, 2012, 6, 143-6.	1.1	1
174	HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury. International Journal of Hepatology, 2012, 2012, 1-23.	0.4	31
175	Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1305-1314.	1.5	9
176	ARIES 144 Week Results: Durable Virologic Suppression in HIV-Infected Patients Simplified to Unboosted Atazanavir/Abacavir/Lamivudine. HIV Clinical Trials, 2012, 13, 233-244.	2.0	27
177	Impact of Baseline Virologic, Immunologic, and Demographic Characteristics on Virologic Responses in the Gemini Study. HIV Clinical Trials, 2012, 13, 111-117.	2.0	0
178	A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-NaÃ¯ve HIV-Infected Patients: SPARTAN Study Results. HIV Clinical Trials, 2012, 13, 119-130.	2.0	85
180	Different Baseline Characteristics and Different Outcomes of HIV-Infected Patients Receiving HAART Through Clinical Trials Compared With Routine Care in Mexico. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 155-160.	0.9	11
181	A Randomized Study of Pharmacokinetics, Efficacy, and Safety of 2 Raltegravir Plus Atazanavir Strategies in ART-Treated Adults. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 143-149.	0.9	19
182	A Randomized Comparative 96-Week Trial of Boosted Atazanavir versus Continued Boosted Protease Inhibitor in HIV-1 Patients with Abdominal Adiposity. Antiviral Therapy, 2012, 17, 689-700.	0.6	13
183	Treatment of HIV infection with once-daily regimens. Expert Opinion on Pharmacotherapy, 2012, 13, 2301-2317.	0.9	27
184	Clinical Significance of Hyperbilirubinemia Among HIV-1â€“Infected Patients Treated with Atazanavir/Ritonavir Through 96 Weeks in the CASTLE Study. AIDS Patient Care and STDs, 2012, 26, 259-264.	1.1	26
185	Efficacy and Safety Outcomes Among Treatment-Experienced Women and Men Treated with Etravirine in Gender, Race and Clinical Experience. AIDS Research and Human Retroviruses, 2012, 28, 544-551.	0.5	12

#	Article	IF	Citations
186	Combination Nucleoside/Nucleotide Reverse Transcriptase Inhibitors for Treatment of HIV Infection. Expert Opinion on Pharmacotherapy, 2012, 13, 65-79.	0.9	18
187	Darunavir: a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection. Expert Opinion on Pharmacotherapy, 2012, 13, 1363-1375.	0.9	13
188	Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naÃ¯ve and -experienced United Kingdom patients in 2011. Journal of Medical Economics, 2012, 15, 796-806.	1.0	7
189	Data-intensive analysis of HIV mutations. , 2012, , .		0
190	Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. Clinical Microbiology and Infection, 2012, 18, E299-E304.	2.8	23
191	AnÃ¡lisis de costes y de coste/eficacia de las pautas preferentes de GESIDA para el tratamiento antirretroviral inicial el 2011. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2012, 30, 168-169.	0.3	2
194	HIV-1 Antiretroviral Resistance. Drugs, 2012, 72, e1-e25.	4.9	260
196	AnÃ¡lisis de costes y de coste/eficacia de las pautas preferentes de GESIDA/Plan Nacional sobre el Sida en 2012 para el tratamiento antirretroviral inicial. Respuesta de los autores. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2012, 30, 511-512.	0.3	2
197	Hyperbilirubinemia during therapy with atazanavir boosted with ritonavir in HIV-infected patients in Lodz region. HIV and AIDS Review, 2012, 11, 54-56.	0.1	1
198	Efficacy and safety of switching suppressed patients with elevated triglycerides from lopinavir/ritonavir or fosamprenavir/ritonavir to atazanavir/ritonavir or darunavir/ritonavir based therapy: The LARD study. HIV and AIDS Review, 2012, 11, 77-83.	0.1	2
199	Gastrointestinal disorders in HIV including diarrhea. , 2012, , 237-247.		1
200	Virological efficacy and safety of antiretroviral therapy-switch to atazanavir-based regimen: a review of the literature. Expert Opinion on Pharmacotherapy, 2012, 13, 2355-2367.	0.9	2
201	Long-Term Use of Atazanavir in the Treament of HIV-Infected patients. Clinical Medicine Insights Therapeutics, 2012, 4, CMT.S5764.	0.4	2
202	New strategies for lowering the costs of antiretroviral treatment and care for people with HIV/AIDS in the United Kingdom. ClinicoEconomics and Outcomes Research, 2012, 4, 193.	0.7	20
203	Antiretroviral Treatment of Adult HIV Infection. JAMA - Journal of the American Medical Association, 2012, 308, 387-402.	3.8	1,239
204	Treating Women with HIV: Is it Different than Treating Men?. Current HIV/AIDS Reports, 2012, 9, 171-178.	1.1	27
205	British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Medicine, 2012, 13, 1-6.	1.0	149
207	10.0â€,List of abbreviations. HIV Medicine, 2012, 13, 84-84.	1.0	2

#	Article	IF	Citations
208	11.0â€,List of appendices. HIV Medicine, 2012, 13, 85-85.	1.0	1
209	1.0â€,Introduction. HIV Medicine, 2012, 13, 7-10.	1.0	1
214	6.0â€,Supporting patients on therapy. HIV Medicine, 2012, 13, 35-46.	1.0	1
216	8.0â€,Antiretroviral therapy in specific populations. HIV Medicine, 2012, 13, 57-81.	1.0	1
219	Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: results from an extended follow-up. Clinical Microbiology and Infection, 2013, 19, E542-E544.	2.8	18
220	Long-Term Efficacy and Safety of Atazanavir/Ritonavir Treatment in a Real-Life Cohort of Treatment-Experienced Patients with HIV Type 1 Infection. AIDS Research and Human Retroviruses, 2013, 29, 564-573.	0.5	9
221	Outcomes of Second Combination Antiretroviral Therapy Regimens Among HIV-Infected Persons in Clinical Care: A Multicenter Cohort Study. AIDS Research and Human Retroviruses, 2013, 29, 574-580.	0.5	8
222	Inflammatory Biomarker Changes and Their Correlation with Framingham Cardiovascular Risk and Lipid Changes in Antiretroviral-Naive HIV-Infected Patients Treated for 144 Weeks with Abacavir/Lamivudine/Atazanavir with or without Ritonavir in ARIES. AIDS Research and Human Retroviruses, 2013, 29, 350-358.	0.5	20
223	Switching to darunavir/ritonavir 800/100â€‰mg onceâ€daily containing regimen maintains virological control in fully suppressed preâ€treated patients infected with HIVâ€1. Journal of Medical Virology, 2013, 85, 8-15.	2.5	13
224	Komentarz do rekomendacji PTN AIDS 2013 â€“ rozpoczynanie i monitorowanie leczenia antyretrowirusowego. HIV and AIDS Review, 2013, 12, 109-112.	0.1	0
226	Final 192â€week efficacy and safety of onceâ€daily darunavir/ritonavir compared with lopinavir/ritonavir in <scp>HIV</scp>â€1â€infected treatmentâ€naÃ¯ve patients in the <scp>ARTEMIS</scp> trial. HIV Medicine, 2013, 14, 49-59.	3.0	149
227	Antiretroviral drug-related toxicities â€“ clinical spectrum, prevention, and management. Expert Opinion on Drug Safety, 2013, 12, 697-707.	1.0	23
228	Impact of baseline HIVâ€1 RNA levels on initial highly active antiretroviral therapy outcome: a metaâ€analysis of 12,370 patients in 21 clinical trials*. HIV Medicine, 2013, 14, 284-292.	1.0	25
230	Design of HIV noninferiority trials. Aids, 2013, 27, 653-657.	1.0	5
231	Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort. Journal of Antimicrobial Chemotherapy, 2013, 68, 200-205.	1.3	14
232	Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1â€“Infected Patients: Week 48 Results. Journal of Infectious Diseases, 2013, 208, 32-39.	1.9	104
233	Adherence Profiles and Therapeutic Responses of Treatment-Naive HIV-Infected Patients Starting Boosted Atazanavir-Based Therapy in the ANRS 134-COPHAR 3 Trial. Antimicrobial Agents and Chemotherapy, 2013, 57, 2265-2271.	1.4	31
234	Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial. Journal of Antimicrobial Chemotherapy, 2013, 68, 690-696.	1.3	13

#	Article	IF	Citations
235	Impact of UGT1A1 Gilbert Variant on Discontinuation of Ritonavir-Boosted Atazanavir in AIDS Clinical Trials Group Study A5202. Journal of Infectious Diseases, 2013, 207, 420-425.	1.9	25
236	A Randomized Controlled Trial to Assess Safety, Tolerability, and Antepartum Viral Load with Increased Lopinavir/Ritonavir Dosage in Pregnancy. AIDS Patient Care and STDs, 2013, 27, 589-595.	1.1	10
237	Telaprevir in HIV/HCV-coinfected patients: a new standard with a short half-life. Future Virology, 2013, 8, 735-743.	0.9	0
238	What Do We Know about Antiretroviral Treatment of HIV in Women?. Antiviral Therapy, 2013, 18, 27-34.	0.6	16
239	Maternal Atazanavir Usage in HIV-Infected Pregnant Women and the Risk of Maternal and Neonatal Hyperbilirubinemia. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, e158-e159.	0.9	2
240	Evaluation of Four Tenofovir-Containing Regimens as First-Line Treatments in Cameroon and Senegal: The Anrs 12115 Dayana Trial. Antiviral Therapy, 2014, 19, 51-59.	0.6	13
241	Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDS. HIV/AIDS - Research and Palliative Care, 2013, 5, 153.	0.4	16
242	An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients. HIV/AIDS - Research and Palliative Care, 2013, 5, 231.	0.4	5
244	Long-Term Gender-Based Outcomes for Atazanavir/Ritonavir (ATV/r)- Containing Regimens in Treatment-Experienced Patients with HIV. Current HIV Research, 2013, 11, 333-341.	0.2	8
245	Cost-Utility Analysis of Lopinavir/Ritonavir versus Atazanavir + Ritonavir Administered as First-Line Therapy for the Treatment of HIV Infection in Italy: From Randomised Trial to Real World. PLoS ONE, 2013, 8, e57777.	1.1	13
247	48-Week Efficacy and Safety of Dolutegravir Relative to Commonly Used Third Agents in Treatment-Naive HIV-1â€“Infected Patients: A Systematic Review and Network Meta-Analysis. PLoS ONE, 2014, 9, e105653.	1.1	63
248	Trends in First-Line Antiretroviral Therapy in Asia: Results from the TREAT Asia HIV Observational Database. PLoS ONE, 2014, 9, e106525.	1.1	18
249	Increasing the use of secondâ€line therapy is a costâ€effective approach to prevent the spread of drugâ€resistant HIV: a mathematical modelling study. Journal of the International AIDS Society, 2014, 17, 19164.	1.2	26
250	Lopinavir/r no longer recommended as a firstâ€line regimen: a comparative effectiveness analysis. Journal of the International AIDS Society, 2014, 17, 19070.	1.2	6
251	Metabolic Effects of Ritonavir-boosted Atazanavir and Darunavir in HIVnegative Adults: A Randomised Comparison. Journal of AIDS & Clinical Research, 2014, 05, .	0.5	0
252	Use of HMG-CoA Reductase Inhibitors in the HIV Population: Implications for Individualized Treatment Selection. Journal of Managed Care Pharmacy, 2014, 20, 262-272.	2.2	2
253	Clinical course and quality of care in ART-naÃ¯ve patients newly presenting in a HIV outpatient clinic. Infection, 2014, 42, 849-857.	2.3	8
256	HIV Protease Inhibitor Resistance. , 2014, , 1-31.		1

#	Article	IF	Citations
257	Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay. Journal of Antimicrobial Chemotherapy, 2014, 69, 2819-2825.	1.3	9
258	Antiretroviral therapy and tuberculosis: does the regimen matter?. Expert Review of Anti-Infective Therapy, 2014, 12, 5-7.	2.0	0
259	Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials. Clinical Infectious Diseases, 2014, 58, 1297-1307.	2.9	293
260	Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir. HIV Medicine, 2014, 15, 330-338.	1.0	25
261	Unplanned antiretroviral treatment interruptions, genetic barrier, and development of resistance. HIV Medicine, 2014, 15, 193-195.	1.0	4
263	7.0â€,Managing virological failure. HIV Medicine, 2014, 15, 48-57.	1.0	2
267	11.0â€,List of appendices. HIV Medicine, 2014, 15, 85-85.	1.0	4
268	2.0â€,Recommendations and auditable outcomes. HIV Medicine, 2014, 15, 11-18.	1.0	2
270	Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions. HIV Medicine, 2014, 15, 224-232.	1.0	6
271	1.0â€,Introduction. HIV Medicine, 2014, 15, 7-10.	1.0	11
272	Efficacy of Tenofovir 1% Vaginal Gel in Reducing the Risk of HIV-1 and HSV-2 Infection. Clinical Medicine Insights Women's Health, 2014, 7, CMWH.S10353.	0.6	30
273	Noninfectious Diarrhea in HIV Seropositive Individuals: a Review of Prevalence Rates, Etiology, and Management in the Era of Combination Antiretroviral Therapy. Infectious Diseases and Therapy, 2014, 3, 103-122.	1.8	26
274	MECHANISMS IN ENDOCRINOLOGY: Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients. European Journal of Endocrinology, 2014, 170, R185-R202.	1.9	67
275	Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. Pharmacogenetics and Genomics, 2014, 24, 195-203.	0.7	37
276	Ginger for prevention of antiretroviral-induced nausea and vomiting: a randomized clinical trial. Expert Opinion on Drug Safety, 2014, 13, 859-866.	1.0	24
277	Improved serum cholesterol in paediatric patients switched from suppressive lopinavirâ€based therapy to boosted darunavir or atazanavir: an 18â€month retrospective study. HIV Medicine, 2014, 15, 635-636.	1.0	9
278	Initial therapy for HIV: can less be more?. Lancet Infectious Diseases, The, 2014, 14, 535-537.	4.6	2
279	Comparison of Body Composition Changes Between Atazanavir/Ritonavir and Lopinavir/Ritonavir Each in Combination with Tenofovir/Emtricitabine in Antiretroviral-NaÃ¯ve Patients with HIV-1 Infection. Clinical Drug Investigation, 2014, 34, 287-296.	1.1	11

#	Article	IF	Citations
280	9.0â€,Acknowledgements. HIV Medicine, 2014, 15, 82-83.	1.0	1
281	British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.). HIV Medicine, 2014, 15, 1-6.	1.0	101
283	Antiretroviral Therapy. Infectious Disease Clinics of North America, 2014, 28, 439-456.	1.9	9
284	HIV protease inhibitors in gut barrier dysfunction and liver injury. Current Opinion in Pharmacology, 2014, 19, 61-66.	1.7	15
285	Evaluation of Atazanavir and Darunavir Interactions with Lipids for Developing pH-Responsive Anti-HIV Drug Combination Nanoparticles. Journal of Pharmaceutical Sciences, 2014, 103, 2520-2529.	1.6	29
287	NRTI-sparing regimens yield higher rates of drug resistance than NRTI-based regimens for HIV-1 treatment. Journal of Global Antimicrobial Resistance, 2014, 2, 103-106.	0.9	1
288	Virologic and immunologic effectiveness of darunavir-based salvage therapy in HIV-1-infected adults in a Brazilian clinical practice setting: results of a multicenter and retrospective cohort study. Brazilian Journal of Infectious Diseases, 2014, 18, 1-7.	0.3	10
289	Tratamiento de la infecciÃ³n por el VIH. Medicine, 2014, 11, 2912-2919.	0.0	0
290	Nucleoside-Sparing Antiretroviral Regimens. Current Infectious Disease Reports, 2014, 16, 410.	1.3	1
291	Effectiveness of Efavirenz Compared with Ritonavir-Boosted Protease-Inhibitor-Based Regimens as Initial Therapy for Patients with Plasma HIV-1 RNA above 100,000 Copies/Ml. Antiviral Therapy, 2014, 19, 569-577.	0.6	8
292	A systematic review of the use of atazanavir in women infected with HIV type-1. Antiviral Therapy, 2014, 19, 293-307.	0.6	4
293	Safety and Pharmacokinetics of the HIV-1 Protease Inhibitor TMC310911 Coadministered With Ritonavir in Healthy Participants. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 299-305.	0.9	3
294	Diagnosis of Obstructive Sleep Apnea in Adults. Annals of Internal Medicine, 2015, 162, 455-456.	2.0	1
295	Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials. Scientific Reports, 2015, 5, 8528.	1.6	29
296	Diagnosis of Obstructive Sleep Apnea in Adults. Annals of Internal Medicine, 2015, 162, 455.	2.0	1
297	Treatment of Hepatitis C Virus Infection. Annals of Internal Medicine, 2015, 162, 458.	2.0	0
298	Treatment of Hepatitis C Virus Infection. Annals of Internal Medicine, 2015, 162, 459.	2.0	1
300	Informed Decision Making About Prostate Cancer Screening. Annals of Internal Medicine, 2015, 162, 457.	2.0	1

#	Article	IF	Citations
301	Low-Dose Computed Tomography Screening for Lung Cancer. Annals of Internal Medicine, 2015, 162, 460.	2.0	1
302	Three Nonnucleoside Reverse Transcriptase Inhibitorâ€“Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1. Annals of Internal Medicine, 2015, 162, 460-461.	2.0	0
304	Mercury Poisoning Presenting as Sporadic Creutzfeldtâ€“Jakob Disease: A Case Report. Annals of Internal Medicine, 2015, 162, 462-463.	2.0	5
305	Three Nonnucleoside Reverse Transcriptase Inhibitorâ€“Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1. Annals of Internal Medicine, 2015, 162, 461.	2.0	0
306	Informed Decision Making About Prostate Cancer Screening. Annals of Internal Medicine, 2015, 162, 457-458.	2.0	0
307	Treatment of Hepatitis C Virus Infection. Annals of Internal Medicine, 2015, 162, 458.	2.0	0
308	Treatment of Hepatitis C Virus Infection. Annals of Internal Medicine, 2015, 162, 458.	2.0	0
309	Low-Dose Computed Tomography Screening for Lung Cancer. Annals of Internal Medicine, 2015, 162, 459.	2.0	2
310	Changes to Initial Postexposure Prophylaxis Regimens Between the Emergency Department and Clinic. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, e182-e184.	0.9	3
311	Human immunodeficiency virus (HIV)-related stone disease - a potential new paradigm?. BJU International, 2015, 116, 684-686.	1.3	1
312	Twenty years of boosting antiretroviral agents. Aids, 2015, 29, 2229-2233.	1.0	9
313	Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1â€“Infected Patients Starting Efavirenz, Lopinavirâ€“Ritonavir, or Atazanavirâ€“Ritonavir Plus Tenofovir/Emtricitabine. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 206-215.	0.9	14
314	Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 312-318.	0.9	10
315	Three Nonnucleoside Reverse Transcriptase Inhibitorâ€“Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1. Annals of Internal Medicine, 2015, 162, 461-462.	2.0	3
316	Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens. PLoS ONE, 2015, 10, e0124666.	1.1	6
317	Factors Associated with the Development of Drug Resistance Mutations in HIV-1 Infected Children Failing Protease Inhibitor-Based Antiretroviral Therapy in South Africa. PLoS ONE, 2015, 10, e0133452.	1.1	24
318	Antiretroviral Therapy for Human Immunodeficiency Virus Infection. , 2015, , 1622-1641.e6.		7
319	Changes in Bone Mineral Density After 96 Weeks of Treatment With Atazanavir/Ritonavir or Lopinavir/Ritonavir Plus Tenofovir DF/Emtricitabine in Treatment-Naive Patients With HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 40-45.	0.9	9

#	Article	IF	Citations
320	Differential Body Composition Effects of Protease Inhibitors Recommended for Initial Treatment of HIV Infection: A Randomized Clinical Trial. Clinical Infectious Diseases, 2015, 60, 811-820.	2.9	26
321	Tenofovir: What We Have Learnt After 7.5ÂMillion Person-Years of Use. Infectious Diseases and Therapy, 2015, 4, 145-157.	1.8	31
323	Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia. Open Forum Infectious Diseases, 2015, 2, ofv085.	0.4	19
324	Boosted Lopinavirâ€“ Versus Boosted Atazanavirâ€“Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. Clinical Infectious Diseases, 2015, 60, 1262-1268.	2.9	6
325	Significant Reduction in HIV Virologic Failure During a 15-Year Period in a Setting With Free Healthcare Access. Clinical Infectious Diseases, 2015, 60, 463-472.	2.9	27
326	When can HIV clinical trials detect treatment effects on drug resistance?. International Journal of STD and AIDS, 2015, 26, 268-278.	0.5	1
327	Dual treatment with atazanavirâ€“ritonavir plus lamivudine versus triple treatment with atazanavirâ€“ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Lancet Infectious Diseases, The, 2015, 15, 775-784.	4.6	122
328	An Evaluation of Statistical Methods for Analyzing Follow-Up Gaussian Laboratory Data with a Lower Quantification Limit. Journal of Biopharmaceutical Statistics, 2015, 25, 812-829.	0.4	1
329	Trends in prevalence of diarrhoea, Kaposiâ€™s sarcoma, bacterial pneumonia, malaria and geohelminths among HIV positive individuals in Uganda. AIDS Research and Therapy, 2015, 12, 20.	0.7	5
330	Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2015, 33, 156-165.	0.3	12
331	Data-intensive analysis of HIV mutations. BMC Bioinformatics, 2015, 16, 35.	1.2	1
332	Long-term Safety and Efficacy of Atazanavir-based Therapy in HIV-infected Infants, Children and Adolescents. Pediatric Infectious Disease Journal, 2015, 34, 162-167.	1.1	19
333	Cost-Effectiveness of Genotype Testing for Primary Resistance in Brazil. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 152-161.	0.9	11
335	A Simple, Efficient, and Sensitive Method for Simultaneous Detection of Anti-HIV Drugs Atazanavir, Ritonavir, and Tenofovir by Use of Liquid Chromatography-Tandem Mass Spectrometry. Antimicrobial Agents and Chemotherapy, 2015, 59, 6682-6688.	1.4	15
336	Efficacy and safety of lopinavir/ritonavir-based antiretroviral therapy in HIV-1-infected subjects with advanced disease: a systematic review and meta-analysis. Future Virology, 2015, 10, 949-959.	0.9	0
337	Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy. Contraception, 2015, 91, 71-75.	0.8	16
338	Chronic Liver Disease in the Human Immunodeficiency Virus Patient. Clinics in Liver Disease, 2015, 19, 1-22.	1.0	25
339	Non-Hepatic Adverse Effects of Antiretroviral Therapy for HIV Treatment and Care. Journal of Infectious Disease and Therapy, 2016, 04, .	0.1	0

#	Article	IF	Citations
340	Antiretroviral Agent. , 0, , 169-214.		1
341	Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection. HIV/AIDS - Research and Palliative Care, 2016, 8, 47.	0.4	9
343	Frequency and distribution patterns of opportunistic infections associated with HIV/AIDS in Uganda. BMC Research Notes, 2016, 9, 501.	0.6	47
344	Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial. Lancet HIV,the, 2016, 3, e343-e350.	2.1	26
345	Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial). Journal of Antimicrobial Chemotherapy, 2016, 71, 2252-2261.	1.3	7
346	HIV-1 drug resistance and resistance testing. Infection, Genetics and Evolution, 2016, 46, 292-307.	1.0	215
347	Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. Lancet HIV,the, 2016, 3, e510-e520.	2.1	151
348	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clinical Pharmacology and Therapeutics, 2016, 99, 363-369.	2.3	161
349	British HIV Association guidelines for the treatment of <scp>HIV</scp>â€1â€positive adults with antiretroviral therapy 2015. HIV Medicine, 2016, 17, s2-s104.	1.0	78
350	Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy. Current HIV/AIDS Reports, 2016, 13, 297-308.	1.1	16
351	Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial. HIV Clinical Trials, 2016, 17, 72-77.	2.0	15
352	Comparison of models for analyzing two-group, cross-sectional data with a Gaussian outcome subject to a detection limit. Statistical Methods in Medical Research, 2016, 25, 2733-2749.	0.7	11
353	Lack of an Effect of Ritonavir Alone and Lopinavir-Ritonavir on the Pharmacokinetics of Fenofibric Acid in Healthy Volunteers. Pharmacotherapy, 2016, 36, 49-56.	1.2	10
354	Prediction of area under the concentrationâ€“time curve for lopinavir from peak or trough lopinavir concentrations in patients receiving lopinavirâ€“ritonavir therapy. American Journal of Health-System Pharmacy, 2016, 73, 376-385.	0.5	2
355	Updates on the Pharmacologic Treatment of Individuals with Human Immunodeficiency Virus. Nursing Clinics of North America, 2016, 51, 45-56.	0.7	2
356	Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-NaÃ¯ve Patients with HIV-1 Infection: the REMAIN Study. HIV Clinical Trials, 2016, 17, 17-28.	2.0	4
357	Backbones versus core agents in initial ART regimens: one game, two players. Journal of Antimicrobial Chemotherapy, 2016, 71, 856-861.	1.3	15
358	Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2016, 34, 361-371.	0.3	10

#	Article	IF	Citations
359	Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study. Journal of Microbiology, Immunology and Infection, 2017, 50, 789-797.	1.5	4
360	Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice) Tj ETQq1 1 0.784314 rgBT /Over	1.6	6
361	Emtricitabine + tenofovir alafenamide for the treatment of HIV. Expert Opinion on Pharmacotherapy, 2017, 18, 427-432.	0.9	10
362	Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial. Antiviral Therapy, 2017, 23, 21-32.	0.6	1
363	HIV Protease Inhibitor Resistance. , 2017, , 567-602.		2
364	Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis. Archives of Virology, 2017, 162, 2181-2190.	0.9	9
365	Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2017, 35, 88-99.	0.2	0
366	Drugs for HIV Infection. , 2017, , 1293-1308.e2.		17
367	Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 88-99.	0.3	12
368	Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines. Journal of the International AIDS Society, 2017, 20, 21396.	1.2	20
369	HIV update: Impact on chronic diseases. Pharmacy Today, 2017, 23, 57-69.	0.0	2
370	Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial. Current HIV Research, 2017, 15, 216-224.	0.2	5
371	Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infectious Diseases, 2017, 17, 551.	1.3	112
372	Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks. HIV/AIDS - Research and Palliative Care, 2017, Volume 9, 51-61.	0.4	4
373	Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort. HIV Clinical Trials, 2018, 19, 52-60.	2.0	6
374	Genetic Contributions and Personalized Medicine. , 2018, , 3-16.		1
375	Longâ€term effectiveness of recommended boosted protease inhibitorâ€based antiretroviral therapy in Europe. HIV Medicine, 2018, 19, 324-338.	1.0	4
376	Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment. Drugs, 2018, 78, 163-201.	4.9	110

#	Article	IF	Citations
377	Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir. Journal of Medicinal Chemistry, 2018, 61, 62-80.	2.9	98
378	Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS) Tj ETQq1 1 0.784314 rgBT /Overlock 1	1.3	2
379	Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate. Current Opinion in HIV and AIDS, 2018, 13, 315-319.	1.5	4
380	Safety and Efficacy of Atazanavir Powder and Ritonavir in HIV-1-Infected Infants and Children From 3 Months to <11 Years of Age. Pediatric Infectious Disease Journal, 2018, 37, e149-e156.	1.1	3
381	Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation. Pharmacogenetics and Genomics, 2018, 28, 1-6.	0.7	4
382	HIV virologic response better with single-tablet once daily regimens compared to multiple-tablet daily regimens. SAGE Open Medicine, 2018, 6, 205031211881691.	0.7	10
383	PharmGKB summary. Pharmacogenetics and Genomics, 2018, 28, 127-137.	0.7	5
384	Symtuza (DRV/c/FTC/TAF) en el tratamiento de inicio. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 17-21.	0.3	1
385	Three HIV Drugs, Atazanavir, Ritonavir, and Tenofovir, Coformulated in Drug-Combination Nanoparticles Exhibit Long-Acting and Lymphocyte-Targeting Properties in NonhumanÂPrimates. Journal of Pharmaceutical Sciences, 2018, 107, 3153-3162.	1.6	36
386	Comparison of 48â€week efficacies of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and nucleoside/nucleotide reverse transcriptase inhibitorâ€sparing regimens: a systematic review and network metaâ€analysis. HIV Medicine, 2018, 19, 559-571.	1.0	3
387	Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection. Expert Opinion on Pharmacotherapy, 2019, 20, 1719-1729.	0.9	10
388	Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naÃ¯ve patients infected with HIV-1: a systematic review and network meta-analysis. BMC Infectious Diseases, 2019, 19, 484.	1.3	38
389	Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patients. International Journal of Infectious Diseases, 2019, 83, 64-71.	1.5	11
390	An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir. BMC Infectious Diseases, 2019, 19, 280.	1.3	4
391	Efficient synthesis of an antiviral drug intermediate using an enhanced short-chain dehydrogenase in an aqueous-organic solvent system. Applied Microbiology and Biotechnology, 2019, 103, 4417-4427.	1.7	12
392	Longitudinal trends in base antiretroviral therapy utilization for human immunodeficiency virus from 2000 to 2016. JACCP Journal of the American College of Clinical Pharmacy, 2019, 2, 32-39.	0.5	2
393	Effectiveness of integrase strand transfer inhibitors among treatment-experienced patients in a clinical setting. Aids, 2019, 33, 1187-1195.	1.0	9
394	Long-term treatment with atazanavir (ATV) in real life in Belgium: a retrospective observational cohort of 2264 HIV patients. Acta Clinica Belgica, 2019, 74, 143-150.	0.5	0

#	Article	IF	Citations
395	Uridine diphosphate glucuronosyltransferase 1A1. Xenobiotica, 2020, 50, 64-76.	0.5	21
396	Potential protease inhibitors and their combinations to block SARS-CoV-2. Journal of Biomolecular Structure and Dynamics, 2022, 40, 903-917.	2.0	15
397	Atazanavir / ritonavir versus Lopinavir / ritonavir-based combined antiretroviral therapy (cART) for HIV-1 infection: a systematic review and meta-analysis. African Health Sciences, 2020, 20, 91-101.	0.3	6
398	Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. Journal of Infection, 2020, 81, e1-e5.	1.7	407
399	Treatment modification after starting cART in people living with HIV: retrospective analysis of the German ClinSurv HIV Cohort 2005â€“2017. Infection, 2020, 48, 723-733.	2.3	9
400	Pharmacogenomics in Asian Subpopulations and Impacts on Commonly Prescribed Medications. Clinical and Translational Science, 2020, 13, 861-870.	1.5	42
401	The far-reaching HAND of cART: cART effects on astrocytes. Journal of NeuroImmune Pharmacology, 2021, 16, 144-158.	2.1	19
402	Efficient synthesis of an antiviral drug intermediate using overexpressed shortâ€chain dehydrogenase and crossâ€linked enzyme aggregates stabilization. Journal of Chemical Technology and Biotechnology, 2021, 96, 714-722.	1.6	2
403	Gastrointestinal manifestations of human immunodeficiency virus and coronavirus disease 2019: Understanding the intersecting regions between the two epidemics. Arab Journal of Gastroenterology, 2021, 22, 75-87.	0.4	2
404	Successful virologic outcomes over time among HAART-treated HIV-infected patients. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2023, 35, 1420-1427.	0.6	1
405	Protease Inhibitors. , 2021, , 139-144.		0
406	HIV Co-Infection Drug Toxicity. , 2012, , 683-699.		1
408	Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-NaÃ¯ve Subjects in the CASTLE Study. PLoS ONE, 2010, 5, e10952.	1.1	108
409	Virologic Failures on Initial Boosted-PI Regimen Infrequently Possess Low-Level Variants with Major PI Resistance Mutations by Ultra-Deep Sequencing. PLoS ONE, 2012, 7, e30118.	1.1	36
410	Description of the L76V Resistance Protease Mutation in HIV-1 B and â€œNon-Bâ€•Subtypes. PLoS ONE, 2013, 8, e54381.	1.1	1
411	Deficient Reporting and Interpretation of Non-Inferiority Randomized Clinical Trials in HIV Patients: A Systematic Review. PLoS ONE, 2013, 8, e63272.	1.1	25
412	Clinical Features and Risk Factors for Atazanavir (ATV)-Associated Urolithiasis: A Case-Control Study. PLoS ONE, 2014, 9, e112836.	1.1	10
413	HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing. PLoS ONE, 2015, 10, e0145772.	1.1	72

#	Article	IF	Citations
414	Safety and Effectiveness of Tenofovir/Emtricitabine or Lamivudine Plus Ritonavir Boosted Atazanavir in Treatment Experienced HIV Infected Adults at Two Urban Private Medical Practices. Journal of Antivirals & Antiretrovirals, 2012, 04, .	0.1	1
415	Endothelial Dysfunction in HIV. , 0, , .		1
416	Adverse Drug Reaction Reports in an Antiretroviral Treatment Centre in Jos, North Central Nigeria. British Journal of Pharmaceutical Research, 2014, 4, 714-721.	0.4	2
417	Antiretroviral Therapy and Communities of Color. , 2009, , 33-51.		0
419	Antiretroviral agents. , 2010, , 427-451.		0
420	Antiretroviral therapy for HIV. , 2010, , 556-566.		1
421	Second line antiretroviral therapy for treatment of HIV in Asia. Asian Biomedicine, 2010, 4, 673-677.	0.2	0
422	Kurse. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2011, , 269-546.	0.0	0
423	Current and Future Treatment Guidelines for HIV. , 2012, , 15-21.		0
424	Long-Term Effectiveness of First-Line Antiretroviral Theraphy in a Cohort of HIV-1 Infected Patients. Journal of Antivirals & Antiretrovirals, 2012, 04, .	0.1	0
425	Effect of Ritonavir-boosting on Atazanavir Discontinuation due to Jaundice in HIV-infected Koreans. Infection and Chemotherapy, 2012, 44, 175.	1.0	1
427	Prevalence and Factors Associated with Opportunistic Infections in HIV Positive Patients on Antiretroviral Therapy in Uganda. International Journal of Tropical Disease & Health, 2015, 10, 1-13.	0.1	0
428	Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort. PLoS ONE, 2016, 11, e0156360.	1.1	0
429	THE EFFECTS OF THE INTENSITY OF CIGARETTE USE AND ANTIRETROVIRAL THERAPY ON THE BLOOD LIPID PROFILE OF AN IRISH HIV PERSON. Journal of Student Research, 2017, 6, 119-125.	0.0	0
430	Inhibiteurs de protÃ©ase. , 2018, , 143-151.		0
431	FGF21 and its Relationship with Inflammatory and Metabolic Parameters in HIV Patients after Antiretroviral Treatment. Current HIV Research, 2020, 18, 308-314.	0.2	2
432	Role of atazanavir in the treatment of HIV infection. Therapeutics and Clinical Risk Management, 2009, 5, 99-116.	0.9	11
433	Challenges in initiating antiretroviral therapy in 2010. Canadian Journal of Infectious Diseases and Medical Microbiology, 2010, 21 Suppl C, 1C-15C.	0.7	0

#	Article	IF	Citations
434	Comparison of the Efficacy and Safety of a Doravirine-Based, Three-Drug Regimen in Treatment-NaÃ¯ve HIV-1 Positive Adults: A Bayesian Network Meta-Analysis. Frontiers in Pharmacology, 2022, 13, 676831.	1.6	2
435	Quality of life and associated factors among people receiving second-line anti-retroviral therapy in Johannesburg, South Africa. BMC Infectious Diseases, 2022, 22, 456.	1.3	3
436	Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations. Pathogens, 2022, 11, 546.	1.2	3
437	Pharmacokinetics of Atazanavir/Ritonavir Once Daily and Lopinavir/Ritonavir Twice and once Daily over 72 h following drug Cessation. Antiviral Therapy, 2008, 13, 901-907.	0.6	32
438	Simplification Strategies to Reduce Antiretroviral drug Exposure: Progress and Prospects. Antiviral Therapy, 2009, 14, 1-12.	0.6	50
439	Temporal and Spatial Distribution of Opportunistic Infections Associated with the Human Immunodeficiency Virus (HIV) in Uganda. Infectious Diseases, 0, , .	4.0	0
440	Genetic Contributions and Personalized Medicine. , 2023, , 3-17.		0